ArticleCornea2026
SMILE-Derived Corneal Stromal Lenticule: Experimental Study as a Corneal Repair Material and Drug Carrier.
Article in Cornea, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preservation and Reuse of KLEx Lenticules: From Biobanking to Therapeutic and Refractive Innovations.Bioengineering (Basel, Switzerland) · 2026Review
- Morphological changes after corneal stromal lenticule excimer laser shaping.Experimental and therapeutic medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeA detailed study of the physicochemical properties of SMILE-derived lenticules and evaluation of their drug delivery after loading with silver nanoparticles (AgNPs).
methodsThe lenticules were decellularized and modified with crosslinking concentrations of 0.01 (0.01E/L), 0.05 (0.05E/L), and 0.25 (0.25E/L) mmol N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) per mg lenticule at 5:1 carbodiimide/N-hydroxysuccinimide (EDC/NHS) ratios. The degree of swelling, light transmittance, biomechanical properties, and stability of the non-crosslinked decellularized lenticules (DLs), 0.01E/L, 0.05E/L, and 0.25E/L were measured and characterized using Fourier transform infrared spectroscopy and transmission electron microscopy with non-crosslinked non-decellularized lenticules as controls. DLs, 0.01E/L, 0.05E/L, and 0.25E/L were soaked in AgNPs for 24 hours, and the concentration of the drug released was measured.
resultsThere was no significant difference in the degree of swelling between the groups ( P > 0.05). The light transmittance of the lenticules did not change after decellularization and crosslinking and decreased after loading with AgNPs. Non-decellularized lenticules biodegraded within 108 to 120 hours, and the other groups biodegraded within 96 to 108 hours in vitro. The 0.01E/L had the highest tensile strength. The absorption peak intensity ratio of the amide I band and the amide II band decreased, and the arrangement of collagen fibers was more compact in crosslinked decellularized lenticules. The 0.01E/L had the highest cumulative drug release (3.4 ± 0.91 μg).
conclusionsCrosslinking decellularization improved the biomechanical properties and resistance to water absorption of lenticules, increased covalent bonds between collagen fibers, and improved drug delivery. Crosslinked decellularized lenticules can be used as a new corneal patch material and drug delivery carrier for drug AgNPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.